Physician profile
Benjamin Franklin Roy
NPI 1013021492
$23,836.35
in general payments reported to CMS, 2019-2025
21 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,774 · 2021: $4,096 · 2022: $1,434 · 2023: $890 · 2024: $1,362 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,301.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,481.92 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $4,581.57 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $1,452.84 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $633.38 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $524.50 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $492.81 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $466.01 | 2022-2025 | Caplyta |
| Indivior INC. | $390.98 | 2022-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $371.10 | 2019-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $341.91 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $322.57 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $227.99 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $176.49 | 2025 | Qelbree |
| Lundbeck LLC | $77.63 | 2019-2025 | Rexulti |
| Sage Therapeutics, LLC | $63.23 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $57.56 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $53.25 | 2022 | |
| Avanir Pharmaceuticals, INC. | $42.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.88 | 2019 | |
| Luye Pharma (USA) Ltd. | $21.43 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.